Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.

Kailayangiri S, Altvater B, Lesch S, Balbach S, Göttlich C, Kühnemundt J, Mikesch JH, Schelhaas S, Jamitzky S, Meltzer J, Farwick N, Greune L, Fluegge M, Kerl K, Lode HN, Siebert N, Müller I, Walles H, Hartmann W, Rossig C.

Mol Ther. 2019 May 8;27(5):933-946. doi: 10.1016/j.ymthe.2019.02.014. Epub 2019 Feb 23.


SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.

Isfort I, Cyra M, Elges S, Kailayangiri S, Altvater B, Rossig C, Steinestel K, Grünewald I, Huss S, Eßeling E, Mikesch JH, Hafner S, Simmet T, Wozniak A, Schöffski P, Larsson O, Wardelmann E, Trautmann M, Hartmann W.

Clin Cancer Res. 2019 Jun 15;25(12):3718-3731. doi: 10.1158/1078-0432.CCR-17-3553. Epub 2019 Feb 27.


Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers.

Rossig C, Kailayangiri S, Jamitzky S, Altvater B.

Front Oncol. 2018 Nov 12;8:513. doi: 10.3389/fonc.2018.00513. eCollection 2018. Review.


T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G.

Spurny C, Kailayangiri S, Altvater B, Jamitzky S, Hartmann W, Wardelmann E, Ranft A, Dirksen U, Amler S, Hardes J, Fluegge M, Meltzer J, Farwick N, Greune L, Rossig C.

Oncotarget. 2017 Dec 22;9(5):6536-6549. doi: 10.18632/oncotarget.23815. eCollection 2018 Jan 19.


Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.

Spurny C, Kailayangiri S, Jamitzky S, Altvater B, Wardelmann E, Dirksen U, Hardes J, Hartmann W, Rossig C.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26719. Epub 2017 Sep 4.


Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Kailayangiri S, Altvater B, Spurny C, Jamitzky S, Schelhaas S, Jacobs AH, Wiek C, Roellecke K, Hanenberg H, Hartmann W, Wiendl H, Pankratz S, Meltzer J, Farwick N, Greune L, Fluegge M, Rossig C.

Oncoimmunology. 2016 Oct 28;6(1):e1250050. doi: 10.1080/2162402X.2016.1250050. eCollection 2017.


Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.

Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, Clifton-Hadley L, Champion K, Sattar Z, Popova B, Hackshaw A, Smith P, Roberts T, Biagi E, Dreno B, Rousseau R, Kailayangiri S, Ahlmann M, Hough R, Kremens B, Sauer MG, Veys P, Goulden N, Cummins M, Amrolia PJ.

Leukemia. 2017 May;31(5):1087-1095. doi: 10.1038/leu.2017.39. Epub 2017 Jan 27.


PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.

Albring JC, Inselmann S, Sauer T, Schliemann C, Altvater B, Kailayangiri S, Rössig C, Hartmann W, Knorrenschild JR, Sohlbach K, Groth C, Lohoff M, Neubauer A, Berdel WE, Burchert A, Stelljes M.

Bone Marrow Transplant. 2017 Feb;52(2):317-320. doi: 10.1038/bmt.2016.274. Epub 2016 Nov 28. No abstract available.


Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.

Jamitzky S, Krueger AC, Janneschuetz S, Piepke S, Kailayangiri S, Spurny C, Rossig C, Altvater B.

Pediatr Blood Cancer. 2015 Nov;62(11):1979-85. doi: 10.1002/pbc.25619. Epub 2015 Jul 1.


Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.

Altvater B, Kailayangiri S, Theimann N, Ahlmann M, Farwick N, Chen C, Pscherer S, Neumann I, Mrachatz G, Hansmeier A, Hardes J, Gosheger G, Juergens H, Rossig C.

Cancer Immunol Immunother. 2014 Oct;63(10):1047-60. doi: 10.1007/s00262-014-1574-3. Epub 2014 Jun 28.


Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function.

Leuchte K, Altvater B, Hoffschlag S, Potratz J, Meltzer J, Clemens D, Luecke A, Hardes J, Dirksen U, Juergens H, Kailayangiri S, Rossig C.

Oncol Rep. 2014 Aug;32(2):845-52. doi: 10.3892/or.2014.3269. Epub 2014 Jun 13.


Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging.

Liebsch L, Kailayangiri S, Beck L, Altvater B, Koch R, Dierkes C, Hotfilder M, Nagelmann N, Faber C, Kooijman H, Ring J, Vieth V, Rossig C.

Br J Cancer. 2013 Aug 6;109(3):658-66. doi: 10.1038/bjc.2013.356. Epub 2013 Jul 9.


Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells.

Mueller SK, Altvater B, Chen C, Kailayangiri S, Ahlmann M, Dirksen U, Juergens H, Rossig C.

Oncol Rep. 2013 Jun;29(6):2348-54. doi: 10.3892/or.2013.2350. Epub 2013 Mar 19.


The ubiquitin-fold modifier 1 (Ufm1) cascade of Caenorhabditis elegans.

Hertel P, Daniel J, Stegehake D, Vaupel H, Kailayangiri S, Gruel C, Woltersdorf C, Liebau E.

J Biol Chem. 2013 Apr 12;288(15):10661-71. doi: 10.1074/jbc.M113.458000. Epub 2013 Feb 28.


The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.

Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, Titze U, Leuchte K, Landmeier S, Hotfilder M, Dirksen U, Hardes J, Gosheger G, Juergens H, Rossig C.

Br J Cancer. 2012 Mar 13;106(6):1123-33. doi: 10.1038/bjc.2012.57. Epub 2012 Feb 28.


Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.

Altvater B, Pscherer S, Landmeier S, Kailayangiri S, Savoldo B, Juergens H, Rossig C.

Cancer Immunol Immunother. 2012 Mar;61(3):385-96. doi: 10.1007/s00262-011-1111-6. Epub 2011 Sep 18.


2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.

Altvater B, Landmeier S, Pscherer S, Temme J, Schweer K, Kailayangiri S, Campana D, Juergens H, Pule M, Rossig C.

Clin Cancer Res. 2009 Aug 1;15(15):4857-66. doi: 10.1158/1078-0432.CCR-08-2810. Epub 2009 Jul 28.

Supplemental Content

Loading ...
Support Center